Targets › FCGR3A
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Sep 2027.
Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC). (UniProt, P08637)
Open in Phaseline: the race on FCGR3A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | bemarituzumab Fibroblast growth factor receptor 2 inhibitor; Low affinity immunoglobulin gamma Fc region receptor III-A binding agent | FGFR2, FCGR3A | Phase 2 | Metastatic Gastro-esophageal Adenocarcinoma | Sep 2027 |
| Chunji Gao | Donor-derived CD123-CD16 bispecific antibody-modified NK cells CD123-CD16 bispecific antibody-modified NK cells for AML targeting | CD123, FCGR3A | Phase 1 | AML (Acute Myelogenous Leukemia) | – |
Metastatic Gastro-esophageal Adenocarcinoma (1) AML (Acute Myelogenous Leukemia) (1)
antibody (1), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.